Neuralink Corp., Elon Musk's brain-implant company, said it received approval from the US Food and Drug Administration to conduct human clinical trials. "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," the company said Thursday in a tweet. The FDA and Neuralink did not immediately respond to requests for comment. Musk's startup is developing a small device that will link the brain to a computer, consisting of electrode-laced wires. Placing the device requires drilling into the skull. The approval "is really a big deal," said Cristin Welle, a former FDA official and an associate professor of neurosurgery and physiology at the University of Colorado.

Synchron, a brain-computer interface startup, reportedly implanted its first device in a US patient earlier this month -- overtaking Elon Musk's Neuralink for the third time. The startup implanted a 1.5-inch device into the brain of an ALS patient at Mount Sinai West medical center in New York on July 6, Bloomberg first reported. A spokesperson from Synchron did not immediately respond to a request for comment. The purpose of the device is to allow the patient to communicate -- even after they have lost the ability to move -- by using their thoughts to send emails and texts. Bloomberg reported that Synchron has already implanted the device in four patients in Australia who have been able to use the brain implant to send messages on WhatsApp and shop online.